Detection of carriers in the Ashkenazi Jewish Population: An objective comparison of high-throughput genotyping versus gene-by-gene testing

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 10, 2013, Pages 763-767

  Klugman, Susan ^a   Schreiber Agus, Nicole ^a,b   Nazareth, Shivani ^c   Evans, Eric A ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JACOBI MEDICAL CENTER   (United States)

^c Program for Jewish Genetic Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA;

ACCURACY; ARTICLE; COMMUNITY SAMPLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GENE BY GENE TESTING; GENETIC DISORDER; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HETEROZYGOTE DETECTION; HIGH THROUGHPUT GENOTYPING; HIGH THROUGHPUT SCREENING; HUMAN; INTERMETHOD COMPARISON; JEW; MUTATIONAL ANALYSIS; NORMAL HUMAN;

FEMALE; GENETIC DISEASES, INBORN; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; JEWS; MALE; MUTATION;

EID: 84884560832     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0105     Document Type: Article

References (17)

1. Bray SM, Mulle JG, Dodd AF, et al. (2010) Signatures of founder effects, admixture, and selection in the Ashkenazi Jewish population. Proc Natl Acad Sci U S A 107:16222-16227
2. Evans JP (2011) Looking ahead, looking behind. Genet Med 13:177-178
3. Gross SJ, Pletcher BA, Monaghan KG (2008) Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 10:54-56
4. Klugman S, Gross SJ (2010) Ashkenazi Jewish screening in the twenty-first century. Obstet Gynecol Clin North Am37:37-46
5. Laberge AM, Watts C, Porter K, Burke W (2010) Assessing the potential success of cystic fibrosis carrier screening: Lessons learned from Tay-Sachs disease and beta-Thalassemia. Public Health Genomics 13:310-319
6. Lazarin G, Haque I, Nazareth S, et al. (2013) An empirical estimate of carrier frequencies for 400 + causal Mendelian variants: Results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med 15:178-186
7. Lee SS, Mountain J, Koenig B, et al. (2008) The ethics of characterizing difference: Guiding principles on using racial categories in human genetics. Genome Biol 9:404
8. Little SE, Janakiraman V, Kaimal A, et al. (2010) The cost-effectiveness of prenatal screening for spinal muscular atrophy. Am J Obstet Gynecol 202:253.e1-253.e17
9. Nakagawa S, Zhan J, Sun W, et al. (2012) Platelet hexosaminidase A enzyme assay effectively detects carriers missed by targeted DNA mutation analysis. JIMD Rep 6:1-6
10. National Human Genome Research Institute (2008) Populationbased carrier screening for single gene disorders: LESSONS learned and new opportunities. Rockville, MD: February 6-7, 2008. Available at www.genome.gov/27026048 (Accessed August 3, 2013
11. National Human Genome Research Institute (2012) DNA sequencing costs: Data from the NHGRI Large-Scale Genome Sequencing Program. Available at www.genome.gov/ sequencing costs (Accessed August 3, 2013
12. Ross LF (2012) A re-examination of the use of ethnicity in prenatal carrier screening. Am J Med Genet 158A:19-23
13. Schneider A, Nakagawa S, Keep R, et al. (2009) Populationbased Tay-Sachs screening among Ashkenazi Jewish young adults in the 21st century: Hexosaminidase A enzyme assay is essential for accurate testing. Am J Med Genet Part A 149A:2444-2447
14. Scott SA, Edelmann L, Liu L, et al. (2010) Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat 31:1240-1250
15. Shore S, Tomczak J, Grebner EE, Myerowitz R (1992) An unusual genotype in an Ashkenazi Jewish patient with Tay-Sachs disease. Hum Mutat 1:486-490
16. Srinivasan BS, Evans EA, Flannick J, et al. (2010) A universal carrier test for the long tail of Mendelian disease. Reprod Biomed Online 21:537-551
17. Tarini BA, Goldenberg AJ (2012) Ethical issues with newborn screening in the genomics era. Annu Rev Genom Hum Genet 13:381-393